Can CG Oncology cover its short-term obligations?

Its current ratio is 31.30 — current assets exceed current liabilities.

Where does CG Oncology's balance sheet data come from?

Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

CG Oncology CGON Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$33.7M-18.7%	$32.49M-87.4%	$45.15M+4.0%	$14.62M—	$41.47M—
Short-term investments	$1.04B+61.1%	$709.67M+46.3%	$635.12M+27.7%	$646.43M—	$646.96M—
Accounts receivable, net	$1.28M+270%	$688K-11.9%	$515K+276%	$562K—	$345K—
Inventories	——	——	——	——	——
Prepaid expenses and other current assets	$63.13M+35.3%	$52.41M+13.4%	$49.55M+22.8%	$47.27M+52.6%	$46.66M+125%
Total current assets	$1.1B+57.2%	$759.48M+0.7%	$695.79M+26.0%	$673.03M—	$701.19M—
Property and equipment, net	$15.07M+5,610%	$15.6M+5,634%	$15.33M+24,232%	$253K—	$264K—
Operating lease right-of-use assets	$4.51M+337%	$3.97M+1,697%	$4.2M+1,428%	$965K—	$1.03M—
Goodwill	——	——	——	——	——
Intangible assets, net	——	——	——	——	——
Other non-current assets	$2.68M-89.4%	$1.68M+1,685%	$114K+115%	$26.68M—	$25.18M—
Total assets	$1.14B+55.9%	$791.59M+4.9%	$729.91M+32.1%	$701.45M—	$728.18M—
Accounts payable	$30.27M+38.7%	$28.76M+45.7%	$29.57M+79.5%	$24.45M+88.3%	$21.82M+155%
Accrued expenses	$25.91M+65.5%	$24.21M+65.1%	$20.42M+80.3%	$22.97M—	$15.66M—
Operating lease liabilities, current	$1.07M+318%	$915K+392%	$912K+305%	$288K—	$255K—
Total current liabilities	$35.22M+55.5%	$30.84M+44.3%	$30.53M+95.3%	$30.38M—	$22.64M—
Long-term debt	——	——	——	——	——
Operating lease liabilities, non-current	$3.51M+349%	$3.11M+5,873%	$3.33M+4,589%	$706K—	$781K—
Operating Lease Liabilities (Total)	$4.58M+342%	$4.02M+1,589%	$4.24M—	$994K—	$1.04M—
Other non-current liabilities	——	——	——	——	——
Total liabilities	$43.48M+85.6%	$38.99M+82.0%	$42.27M+169%	$31.09M—	$23.42M—
Common stock	$9K+12.5%	$8K0.0%	$8K—	$8K—	$8K—
Additional paid-in capital	$1.53B+59.9%	$1.13B+18.9%	$1.03B+41.8%	$964.21M—	$957.18M—
Retained earnings	-$439.18M-74.0%	-$378.98M-73.9%	-$337.67M-81.4%	-$293.86M—	-$252.43M—
Total stockholders' equity	$1.09B+54.9%	$752.6M+2.6%	$687.64M+28.1%	$670.36M+21.4%	$704.76M+23.9%
Total liabilities and stockholders' equity	$1.14B+55.9%	$791.59M+4.9%	$729.91M+32.1%	$701.45M—	$728.18M—
Short- term Investments	$1.04B+61.1%	$709.67M+46.3%	$635.12M+27.7%	$646.43M—	$646.96M—
Deferred Tax Assets and Other Non-Current Assets	$2.68M+419%	$1.68M+1,685%	$114K+115%	$522K—	$516K—
Net Investment in Lease	$4.51M+337%	$3.97M+1,697%	$4.2M+1,428%	$965K—	$1.03M—
Intangible assets — net	——	——	——	——	——
Operating lease right-of-use assets	$4.51M+337%	$3.97M+1,697%	$4.2M+1,428%	$965K—	$1.03M—
Other non-current assets	$2.68M+419%	$1.68M+1,685%	$114K+115%	$522K—	$516K—
Operating Lease Right-of-Use Assets in Other Assets	$4.51M+337%	$3.97M+1,697%	$4.2M+1,428%	$965K—	$1.03M—
Software and Technology Licenses, Net	$2.68M+419%	$1.68M+1,685%	$114K+115%	$522K—	$516K—
Total Liabilities Assumed in Business Combination	——	——	——	——	——
Accrued expenses and other liabilities	$25.91M+65.5%	$24.21M+65.1%	$20.42M+80.3%	$22.97M—	$15.66M—
Total debt	$7.58M+631%	$7.02M+2,850%	$7.24M+2,346%	$994K—	$1.04M—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$9K+12.5%	$8K0.0%	$8K—	$8K—	$8K—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can CG Oncology cover its short-term obligations?: Its current ratio is 31.30 — current assets exceed current liabilities.
Where does CG Oncology's balance sheet data come from?: Every line is extracted from CG Oncology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.